en · de · es · fr · pt
semaglutide-notes.peptides9002.com › Wiki › Background And Molecular Design — What the Evidence Shows

Background And Molecular Design — What the Evidence Shows

By Editorial Desk · published 2026-03-03 · last reviewed 2026-03-26 · Wiki

This is a working overview of deamidation, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-03-26 and is reviewed periodically as new material appears.

Background and Molecular Design

Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.

Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.

The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.

Background and Molecular Profile

The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.

Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.

Semaglutide at a glance

PropertyValueNotes
Molecular class31-amino-acid peptideModified glucagon-like peptide-1 analogue
Molecular massapproximately 4114 DaCalculated for the free peptide backbone
Appearancewhite to off-white powderTypical of purified lyophilised peptide batches
Solubility classfreely soluble in waterAqueous solubility improves at slightly alkaline pH
Typical storage-20 degrees Celsius, dry, darkProtect from repeated freeze-thaw cycles

Handling, Storage, and Analytical Verification

Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.

Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.

Related pages on this site

结构特征与受体作用机制

皮下注射后吸收相对缓慢,绝对生物利用度约为百分之八十九,血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢,终末半衰期约为一百六十五小时,接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升,血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主,相关产物主要经尿液与粪便排出。

序列层面的改动同时解决了两个问题,即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟,主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库,使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发,属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物,其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代,使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸,进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链,该侧链赋予分子与血浆白蛋白结合的能力。

Mechanism and Pharmacological Class

The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.

Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.

Reference notes

=== Opioid agonist === β-Endorphin is an agonist of the opioid receptors; it preferentially binds to the μ-opioid receptor. Evidence suggests that it serves as a primary endogenous ligand for the μ-opioid receptor, the same receptor to which the chemicals extracted from opium, such as morphine, derive their analgesic properties. β-Endorphin has the highest binding affinity of any endogenous opioid for the μ-opioid receptor. Opioid receptors are a class of G-protein coupled receptors, such that when β-endorphin or another opioid binds, a signaling cascade is induced in the cell. Acetylation of the N-terminus of β-endorphin, however, inactivates the neuropeptide, preventing it from binding to its receptor. The opioid receptors are distributed throughout the central nervous system and within the peripheral tissue of neural and non-neural origin. They are also located in high concentrations in the periaqueductal gray, locus coeruleus, and the rostral ventromedial medulla. In addition to the full-length peptide, brain and pituitary tissue also contain shorter β-endorphin fragments such as β-endorphin(1–27), which can act as a competitive antagonist at μ-opioid receptors and attenuate the analgesic effects of β-endorphin(1–31) in experimental models. Voltage-dependent calcium channels (VDCCs) are important membrane proteins that mediate the depolarization of neurons, and play a major role in promoting the release of neurotransmitters. When endorphin molecules bind to opioid receptors, G proteins activate and dissociate into their constituent Gα and Gβγ sub-units.

This is important when considering pharmacological interactions: the tissue concentration of a drug with a plasma protein binding rate of less than 90% is not going to significantly increase if that drug is displaced from its union with a protein by another substance. On the other hand, at binding rates of greater than 95% small changes can cause important modifications in a drug's tissue concentration. This will, in turn, increase the risk of the drug having a toxic effect on tissues. Perhaps the most important plasma proteins are the albumins as they are present in relatively high concentrations and they readily bind to other substances. Other important proteins include the glycoproteins, the lipoproteins and to a lesser degree the globulins. It is therefore easy to see that clinical conditions that modify the levels of plasma proteins (for example, hypoalbuminemias brought on by renal dysfunction) may affect the effect and toxicity of a drug that has a binding rate with plasma proteins of above 90%.

=== Association and dissociation constants === When discussing the properties of acids it is usual to specify equilibrium constants as acid dissociation constants, denoted by Ka, with numerical values given the symbol pKa.

Sources: en.wikipedia.org

Notes from published material

=== Grand Lodge of Colon vs. Provincial Mother Lodge of Havana === By 1870, only seven lodges were left in the entire island of Cuba. On May 26, 1870, the former GOCA Lodges around Havana, distancing themselves from the Colon Freemasonry of Santiago de Cuba, established the First Provincial Mother Lodge of Havana. They elected as Grand Master Severino Fernández Mora, who was a former Spanish Army physician in the Military Health Service of Spain that had been exiled from the country for revolutionary activities and ideas. Quickly, the Supreme Council recalled the warrant for the Mother Lodge. On April 11, 1873, the Grand Lodge of Colon resumed its work, despite the fear of reprisal. In 1875, they arranged with the Supreme Council to secure jurisdiction over Symbolic Masonry and the authority to charter new lodges. In 1873, the Supreme Council sent out a decree that all bodies in Cuba were to be directed by the Consistory. This included the Grand Lodge of Colon. The Supreme Council also decreed that members of the 31st through 33rd Degrees were granted honorary membership at any Lodge in Cuba. On May 23, 1875, the Second Provincial Mother Lodge of Havana was established. In 1875, the Supreme Council sent two delegates to the Congress of Supreme Councils in Lausanne, Switzerland. Freemasons in Cuba were surprised that they were accepted where Spain's delegation was refused attendance. The Cuban representatives, David Elías Pierre and Benjamín Odio, became signatories to the Pact of Confederation of the Supreme Councils which the Congress produced.

where wt = Density of the wound area at time t ct = Density of the cell area at time t The above are basic metrics that can be measured with this assay. However efforts are still being made to improve the interpretation of this assay. Three different measurements: direct rate average, regression rate average and average distance regression rate have been evaluated. Direct rate average and average distance regression rate were more resistant to outliers, whereas regression rate average were more sensitive to outliers.

==== Mechanism of action ==== One of the components in nabiximol, tetrahydrocannabinol (THC), weakly stimulates cannabinoid receptor 1(CBR1) and cannabinoid receptor 2 (CBR2) to produce analgesic effect (pain relief). Another component of nabiximol, cannabidiol (CBD), slightly inhibits the proliferation of T cells (a type of immune cells) and the activity of microglia (cells within the brain that regulate neural activity and repair).

== Education and career == Bhatt graduated Boston Latin School, earned his science degree as a National Merit Scholar from MIT, an MD from Cornell and an MPH from Harvard. He received his Executive MBA from the University of Oxford in 2024. He trained in internal medicine and cardiology at the University of Pennsylvania and Cleveland Clinic, completing fellowships in interventional cardiology and cerebral and peripheral vascular intervention. He served as chief interventional fellow at Cleveland Clinic where he worked as an interventional cardiologist, associate professor of medicine, director of the interventional cardiology fellowship, associate director of the cardiovascular medicine fellowship, and associate director of the cardiovascular coordinating center. Later, he became the Chief of Cardiology at the VA Boston Healthcare System and, subsequently, the Interventional Cardiovascular Programs executive director at Brigham and Women's Hospital. Additionally, he was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. In 2012, he was appointed a professor of medicine at Harvard Medical School.

Sources: en.wikipedia.org

Further detail

== Data produced by structural alignment == The minimum information produced from a successful structural alignment is a set of residues that are considered equivalent between the structures. This set of equivalences is then typically used to superpose the three-dimensional coordinates for each input structure. (Note that one input element may be fixed as a reference and therefore its superposed coordinates do not change.) The fitted structures can be used to calculate mutual RMSD values, as well as other more sophisticated measures of structural similarity such as the global distance test (GDT, the metric used in CASP). The structural alignment also implies a corresponding one-dimensional sequence alignment from which a sequence identity, or the percentage of residues that are identical between the input structures, can be calculated as a measure of how closely the two sequences are related.

== Precursors == The earliest use of chromatography is sometimes attributed to German chemist Friedlieb Ferdinand Runge, who in 1855 described the use of paper to analyze dyes. Runge dropped spots of different inorganic chemicals onto circles of filter paper already impregnated with another chemical, and reactions between the different chemicals created unique color patterns. According to historical analysis of L. S. Ettre, however, Runge's work had "nothing to do with chromatography" (and instead should be considered a precursor of chemical spot tests such as the Schiff test). In the 1860s, Christian Friedrich Schönbein and his student Friedrich Goppelsroeder published the first attempts to study the different rates at which different substances move through filter paper. Schönbein, who thought capillary action (rather than adsorption) was responsible for the movement, called the technique capillary analysis, and Goppelsroeder spent much of his career using capillary analysis to test the movement rates of a wide variety of substances. Unlike modern paper chromatography, capillary analysis used reservoirs of the substance being analyzed, creating overlapping zones of the solution components rather than separate points or bands. Work on capillary analysis continued, but without much technical development, well into the 20th century. The first significant advances over Goppelsroeder's methods came with the work of Raphael E.

EMP, also known as estradiol normustine phosphate, is a combined estrogen ester and nitrogen mustard ester. It consists of estradiol, an estrogen, linked with a phosphate ester as well as an ester of normustine, a nitrogen mustard. In terms of its pharmacodynamic effects, EMP is a prodrug of estramustine, estromustine, and estradiol. As a prodrug of estradiol, EMP is an estrogen and hence an agonist of the estrogen receptors. EMP itself has only very weak affinity for the estrogen receptors. The medication is of about 91% higher molecular weight than estradiol due to the presence of its C3 normustine and C17β phosphate esters. Because EMP is a prodrug of estradiol, it may be considered to be a natural and bioidentical form of estrogen, although it does have additional cytostatic activity via estramustine and estromustine. EMP acts by a dual mechanism of action: 1) direct cytostatic activity via a number of actions; and 2) as a form of high-dose estrogen therapy via estrogen receptor-mediated antigonadotropic and functional antiandrogenic effects. The antigonadotropic and functional antiandrogenic effects of EMP consist of strong suppression of gonadal androgen production and hence circulating levels of androgens such as testosterone; greatly increased levels of sex hormone-binding globulin and hence a decreased fraction of free androgens in the circulation; and direct antiandrogenic actions in prostate cells. The free androgen index with oral EMP has been found to be on average 4.6-fold lower than with orchiectomy.

==== Background ==== The effects of the illegal drug trade in the United States can be seen in a range of political, economic and social aspects. Increasing drug related violence can be tied to the racial tension that arose during the late 20th century along with the political upheaval prevalent throughout the 1960s and 70s. The second half of the 20th century was a period when increased wealth, and increased discretionary spending, increased the demand for illicit drugs in certain areas of the United States. Large-scale drug trafficking is one of the capital crimes, and may result in a death sentence prescribed at the federal level when it involves murder.

Carbon-13 (13C) is a natural, stable isotope of carbon with a nucleus containing six protons, six electrons, and seven neutrons. It constitutes about 1.07% of natural carbon and is one of the so-called environmental isotopes.

Sources: en.wikipedia.org

Frequently asked questions

What class of drug is semaglutide?

It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.

Is semaglutide identical to endogenous GLP-1?

No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.

Why does albumin binding matter?

Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.

What is the relationship between semaglutide and native GLP-1?

It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.

Network